Investigation of the Prevalence of Sarcopenia and Dynapenia According to Disease Stage in Patients With Multiple Sclerosis and Evaluation of the Relationship Between Sarcopenia Severity and Clinical and Functional Parameters

NCT07842731 | Not Yet Recruiting

• 1 other identifier: E-59394181-100-137243
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

This cross-sectional observational study aims to determine the prevalence of sarcopenia and dynapenia across disability stages in patients with multiple sclerosis (MS) and investigate their associations with clinical and functional parameters. Approximately 150 patients will be classified into two groups according to their Expanded Disability Status Scale (EDSS) scores: mild disability (EDSS \< 4.0) and moderate disability (EDSS 4.0-6.5). Sarcopenia and dynapenia will be assessed using the ISarcoPRM algorithm. Physical activity, fatigue, and functional independence will also be evaluated.

Conditions

Multiple Sclerosis; Sarcopenia; Dynapenia

Keywords

Disability Status; Muscle Strength; Muscle Mass; Physical Activity; Fatigue; Functional Independence

Outcome Measures

Primary Outcomes (2)

• Prevalence of Sarcopenia

  Sarcopenia will be classified using the ISarcoPRM algorithm based on low muscle mass (STAR) combined with reduced handgrip strength and/or physical performance. Prevalence will be calculated as the percentage of participants meeting the criteria in each EDSS group.

  Baseline

• Prevalence of Dynapenia

  Dynapenia will be defined as reduced muscle strength, independently of muscle mass, based on low handgrip strength (\<32 kg for men; \<19 kg for women) and/or prolonged five-times sit-to-stand time (≥12 seconds). Prevalence will be calculated as the percentage of participants meeting the criteria in each EDSS group.

  Baseline

Secondary Outcomes (7)

• Handgrip Strength

  Baseline

• Five-Times Sit-to-Stand Test

  Baseline

• Sonographic Thigh Adjustment Ratio (STAR)

  Baseline

• Sarcopenia Risk (SARC-F)

  Baseline

• Modified Fatigue Impact Scale (MFIS)

  Baseline

Study Arms (2)

Mild Disability MS

Patients with multiple sclerosis with an Expanded Disability Status Scale (EDSS) score below 4.0.

Moderate Disability MS

Patients with multiple sclerosis with an Expanded Disability Status Scale (EDSS) score between 4.0 and 6.5.

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Approximately 150 adults diagnosed with multiple sclerosis (MS) receiving care at the Physiotherapy and Rehabilitation Unit of Başkent University Hospital. Participants will be classified into mild (EDSS \<4.0) and moderate (EDSS 4.0-6.5) disability groups.

You may qualify if:

• Aged 18 years or older.
• Diagnosed with multiple sclerosis (MS) by a neurologist.
• Standardized Mini-Mental State Examination (SMMSE) score ≥24.
• Expanded Disability Status Scale (EDSS) score ≤6.5.
• Willing to participate and provide written informed consent.

You may not qualify if:

• Orthopedic surgery within the previous 3 months.
• Botulinum toxin injection within the previous 3 months.
• Severe cognitive impairment affecting the ability to complete assessments.
• Severe cardiopulmonary disease.
• Serious orthopedic or additional neurological conditions that may affect the assessments.
• Severe pain (Visual Analog Scale \[VAS\] score \>7).

Sponsors & Collaborators

• Atılım University: lead
• Baskent University Ankara Hospital: collaborator

Study Sites (1)

Baskent University Ankara Hospital

Ankara, Turkey (Türkiye)

Location

Related Publications (3)

• Ozkeskin M, Ozden F, Ar E, Yuceyar N. The reliability and validity of the 30-second chair stand test and modified four square step test in persons with multiple sclerosis. Physiother Theory Pract. 2023 Oct 3;39(10):2189-2195. doi: 10.1080/09593985.2022.2070811. Epub 2022 Apr 26.

  PMID: 35471847 BACKGROUND

• Severijns D, Lamers I, Kerkhofs L, Feys P. Hand grip fatigability in persons with multiple sclerosis according to hand dominance and disease progression. J Rehabil Med. 2015 Feb;47(2):154-60. doi: 10.2340/16501977-1897.

  PMID: 25268997 BACKGROUND

• Kara M, Kaymak B, Frontera W, Ata AM, Ricci V, Ekiz T, Chang KV, Han DS, Michail X, Quittan M, Lim JY, Bean JF, Franchignoni F, Ozcakar L. Diagnosing sarcopenia: Functional perspectives and a new algorithm from the ISarcoPRM. J Rehabil Med. 2021 Jun 21;53(6):jrm00209. doi: 10.2340/16501977-2851.

  PMID: 34121127 BACKGROUND

MeSH Terms

Conditions

Multiple Sclerosis; Sarcopenia; Motor Activity; Fatigue

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Behavior

Study Officials

• Büşra Seçkinoğulları Korkusuz, PhD

  Ankara University

  PRINCIPAL INVESTIGATOR

• Ayşenur Özcan

  Çankırı Karatekin University

  STUDY CHAIR

• Süleyman Korkusuz

  Atılım University

  STUDY CHAIR

• Ali M Özcan

  Baskent University

  STUDY CHAIR

Central Study Contacts

Süleyman Korkusuz, PhD

CONTACT

+905388675480; suleyman.korkusuz@atilim.edu.tr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assist. Prof. Dr

Study Record Dates

• First Submitted: September 21, 2026
• First Posted: September 25, 2026
• Study Start (Estimated): October 10, 2026
• Primary Completion (Estimated): December 10, 2026
• Study Completion (Estimated): December 20, 2026
• Last Updated: September 25, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)